Last reviewed · How we verify
BMS-986016
At a glance
| Generic name | BMS-986016 |
|---|---|
| Also known as | Anti-LAG-3 (Anti-Lymphocyte Activation Gene-3), relatlimab, Relatlimab |
| Sponsor | Bristol-Myers Squibb |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Fatigue
- Pruritus
- Arthralgia
- Diarrhoea
- Headache
- Nausea
- Rash
- Hypothyroidism
- Decreased appetite
- Anaemia
- Cough
- Asthenia
Key clinical trials
- Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer (PHASE2)
- Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma (PHASE2)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (PHASE2)
- Pan Tumor Rollover Study (PHASE2)
- Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study (PHASE2, PHASE3)
- Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer (PHASE1)
- Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla (PHASE2)
- Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |